Daniel Podzamczer

InstitutionHospital Universitari de Bellvitge
AddressBarcelona
Spain
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 1 Covid-19 publications, with a maximum of 1 publications in June 2021
    All Publications
    Bar chart showing 136 publications over 19 distinct years, with a maximum of 20 publications in 2014
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Berenguer J, Díez C, Martín-Vicente M, Micán R, Pérez-Elías MJ, García-Fraile LJ, Vidal F, Suárez-García I, Podzamczer D, Del Romero J, Pulido F, Iribarren JA, Gutiérrez F, Poveda E, Galera C, Izquierdo R, Asensi V, Portilla J, López JC, Arribas JR, Moreno S, González-García J, Resino S, Jarrín I. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. Clin Microbiol Infect. 2021 Nov; 27(11):1678-1684. PMID: 34186209.
      Citations: 1     Fields:    Translation:Humans
    2. Navarro-Alcaraz A, Tiraboschi J, Gómez C, Candas-Estébanez B, Saumoy M, Imaz A, Podzamczer D. Lack of benefit with omega-3 fatty acid supplementation in HIV patients: A randomized pilot study. HIV Res Clin Pract. 2019 Sep 03; 1-7. PMID: 31478478.
      Citations:    Fields:    
    3. Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, Khuong-Josses MA, Parks D, Angelis K, Kahl LP, Blair EA, Adkison K, Underwood M, Matthews JE, Wynne B, Vandermeulen K, Gartland M, Smith K. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019 09; 6(9):e576-e587. PMID: 31307948.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    4. Prieto P, Podzamczer D. Switching strategies in the recent era of antiretroviral therapy. Expert Rev Clin Pharmacol. 2019 Mar; 12(3):235-247. PMID: 30691315.
      Citations: 1     Fields:    Translation:Humans
    5. Rosado-Sánchez I, Herrero-Fernández I, Genebat M, Del Romero J, Riera M, Podzamczer D, Olalla J, Vidal F, Muñoz-Fernández MA, Leal M, Pacheco YM. HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and a4ß7 on CD4 T-Cells Prior Therapy Initiation. Front Immunol. 2018; 9:1673. PMID: 30073002.
      Citations: 3     Fields:    
    6. Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, López-Cortés L, Ruane P, Podzamczer D, Brinson C, Custodio J, Liu H, Andreatta K, Martin H, Cheng A, Quirk E. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018 07; 5(7):e357-e365. PMID: 29925489.
      Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
    7. Imaz A, Niubó J, Amara A, Khoo S, Ferrer E, Tiraboschi JM, Acerete L, Garcia B, Vila A, Podzamczer D. Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39). J Neurovirol. 2018 08; 24(4):391-397. PMID: 29542028.
      Citations: 2     Fields:    Translation:HumansCells
    8. Winston A, Post FA, DeJesus E, Podzamczer D, Di Perri G, Estrada V, Raffi F, Ruane P, Peyrani P, Crofoot G, Mallon PWG, Castelli F, Yan M, Cox S, Das M, Cheng A, Rhee MS. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial. Lancet HIV. 2018 04; 5(4):e162-e171. PMID: 29475804.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    9. Yong CL, Gathe JC, Knecht G, Orrell C, Mallolas J, Podzamczer D, Trottier B, Zhang W, Sabo JP, Vinisko R, Drulak M, Quinson AM. Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection. HIV Clin Trials. 2017 Nov-Dec; 18(5-6):189-195. PMID: 29210627.
      Citations: 3     Fields:    Translation:HumansCells
    10. Prieto P, Imaz A, Calatayud L, García O, Saumoy M, Podzamczer D. Extracutaneous atypical syphilis in HIV-infected patients. Med Clin (Barc). 2017 Dec 07; 149(11):488-492. PMID: 28739269.
      Citations:    Fields:    Translation:Humans
    11. Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B, de Wet J, Rockstroh J, Lazzarin A, Rijnders B, Podzamczer D, Thalme A, Stoeckle M, Porter D, Liu HC, Cheng A, Quirk E, SenGupta D, Cao H. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017 05; 4(5):e195-e204. PMID: 28259777.
      Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
    12. Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A. Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLoS One. 2017; 12(2):e0172184. PMID: 28182783.
      Citations:    Fields:    
    13. Imaz A, Podzamczer D. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV. Expert Rev Anti Infect Ther. 2017 03; 15(3):195-209. PMID: 28117606.
      Citations: 8     Fields:    Translation:Humans
    14. Saumoy M, Tiraboschi JM, Ordoñez-Llanos J, Ribera E, Domingo P, Mallolas J, Curto J, Gatell JM, Podzamczer D. Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy. HIV Clin Trials. 2017 03; 18(2):49-53. PMID: 28081673.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    15. Saumoy M, Llibre JM, Terrón A, Knobel H, Arribas JR, Domingo P, Arroyo-Manzano D, Rivero A, Moreno S, Podzamczer D. Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice. AIDS Res Hum Retroviruses. 2017 01; 33(1):29-32. PMID: 27250802.
      Citations: 1     Fields:    Translation:Humans
    16. Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A. Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLoS One. 2016; 11(10):e0164455. PMID: 27727331.
      Citations: 4     Fields:    Translation:HumansCells
    17. Cuervo G, Simonetti AF, Alegre O, Sanchez-Salado JC, Podzamczer D. Toxoplasma myocarditis: a rare but serious complication in an HIV-infected late presenter. AIDS. 2016 09 10; 30(14):2253-4. PMID: 27574795.
      Citations: 3     Fields:    Translation:HumansAnimals
    18. Curran A, Rojas J, Cabello A, Troya J, Imaz A, Domingo P, Martinez E, Ryan P, Górgolas M, Podzamczer D, Knobel H, Gutiérrez F, Ribera E. Effectiveness and safety of an abacavir/lamivudine?+?rilpivirine regimen for the treatment of HIV-1 infection in naive patients. J Antimicrob Chemother. 2016 12; 71(12):3510-3514. PMID: 27591292.
      Citations: 3     Fields:    Translation:HumansCells
    19. Imaz A, Martinez-Picado J, Niubó J, Kashuba AD, Ferrer E, Ouchi D, Sykes C, Rozas N, Acerete L, Curto J, Vila A, Podzamczer D. HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen. J Infect Dis. 2016 11 15; 214(10):1512-1519. PMID: 27578849.
      Citations: 8     Fields:    Translation:HumansCells
    20. Llibre JM, de Lazzari E, Molina JM, Gallien S, Gonzalez-García J, Imaz A, Podzamczer D, Clotet B, Domingo P, Gatell JM. Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. Enferm Infecc Microbiol Clin (Engl Ed). 2018 Jan; 36(1):16-20. PMID: 27595183.
      Citations: 2     Translation:Humans
    21. Podzamczer D, Imaz A. Dual antiretroviral therapy: finding a place in the battle. Lancet HIV. 2016 08; 3(8):e335-e336. PMID: 27470021.
      Citations:    Fields:    Translation:Humans
    22. Nicolás D, Esteve A, Cuadros A, Campbell CNJ, Tural C, Podzamczer D, Murillas J, Homar F, Segura F, Force L, Vilaró J, Masabeu À, Garcia I, Mercadal J, Montoliu A, Ferrer E, Riera M, Cifuentes C, Ambrosioni J, Navarro G, Manzardo C, Clotet B, Gatell JM, Casabona J, Miró JM, Murillas J, Manzardo C, Masabeu A, Mercadal J, Cifuentes C, Dalmau D, Domingo P, Falcó V, Curran A, Agustí C, Montoliu A, Pérez I, Curto J, Gargoulas F, Gómez A, Rubia JC, Zamora L, Blanco JL, Garcia-Alcaide F, Martínez E, Mallolas J, Llibre JM, Sirera G, Romeu J, Jou A, Negredo E, Saumoy M, Imaz A, Bolao F, Cabellos C, Peña C, DiYacovo S, Van Den Eynde E, Sala M, Cervantes M, Amengual MJ, Navarro M, Segura V, Barrufet P, Molina J, Alvaro M, Payeras T, Gracia Mateo M, Fernández J. Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection. Clin Infect Dis. 2016 06 15; 62(12):1578-1585. PMID: 27126346.
      Citations: 1     Fields:    Translation:HumansCells
    23. Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA. Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. Enferm Infecc Microbiol Clin. 2016 Oct; 34(8):517-23. PMID: 27056581.
      Citations:    Fields:    Translation:Humans
    24. Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA. Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. Enferm Infecc Microbiol Clin. 2016 Oct; 34(8):516.e1-516.e18. PMID: 26976381.
      Citations: 3     Fields:    Translation:Humans
    25. Dinges W, Girard PM, Podzamczer D, Brockmeyer NH, García F, Harrer T, Lelievre JD, Frank I, Colin De Verdière N, Yeni GP, Ortega Gonzalez E, Rubio R, Clotet Sala B, DeJesus E, Pérez-Elias MJ, Launay O, Pialoux G, Slim J, Weiss L, Bouchaud O, Felizarta F, Meurer A, Raffi F, Esser S, Katlama C, Koletar SL, Mounzer K, Swindells S, Baxter JD, Schneider S, Chas J, Molina JM, Koutsoukos M, Collard A, Bourguignon P, Roman F. The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial. Medicine (Baltimore). 2016 Feb; 95(6):e2673. PMID: 26871794.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    26. Saumoy M, Alonso-Villaverde C, Navarro A, Olmo M, Vila R, Ramon JM, Di Yacovo S, Ferrer E, Curto J, Vernet A, Vila A, Podzamczer D. Randomized trial of a multidisciplinary lifestyle intervention in HIV-infected patients with moderate-high cardiovascular risk. Atherosclerosis. 2016 Mar; 246:301-8. PMID: 26826629.
      Citations: 8     Fields:    Translation:HumansCells
    27. Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, Kilby JM, Lutz T, Podzamczer D, Portilla J, Roth N, Wong D, Granier C, Wynne B, Pappa K. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr. 2015 Dec 15; 70(5):515-9. PMID: 26262777.
      Citations: 69     Translation:HumansCells
    28. Tiraboschi JM, Knobel H, Imaz A, Villar J, Ferrer E, Saumoy M, González A, Rozas N, Vila A, Niubó J, Curto J, Podzamczer D. Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once daily. Antivir Ther. 2016; 21(4):359-63. PMID: 26656921.
      Citations: 2     Fields:    Translation:Humans
    29. Ferrer E, Curto J, Esteve A, Miro JM, Tural C, Murillas J, Segura F, Barrufet P, Casabona J, Podzamczer D. Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status. J Antimicrob Chemother. 2015 Dec; 70(12):3332-8. PMID: 26410171.
      Citations:    Fields:    Translation:HumansCells
    30. Berenguer J, Rivero A, Blasco AJ, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, Lázaro P, López JC, Llibre JM, Lozano F, Miró JM, Podzamczer D, Tuset M, Gatell JM. Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enferm Infecc Microbiol Clin. 2016 Jun-Jul; 34(6):361-71. PMID: 26321131.
      Citations: 2     Fields:    Translation:Humans
    31. Velasco C, Pérez I, Podzamczer D, Llibre JM, Domingo P, González-García J, Puig I, Ayala P, Martín M, Trilla A, Lázaro P, Gatell JM. Prediction of higher cost of antiretroviral therapy (ART) according to clinical complexity. A validated clinical index. Enferm Infecc Microbiol Clin. 2016 Mar; 34(3):149-58. PMID: 26298097.
      Citations:    Fields:    Translation:Humans
    32. Casadellà M, Manzardo C, Noguera-Julian M, Ferrer E, Domingo P, Pérez-Álvarez S, Podzamczer D, Plana M, Clotet B, Gatell JM, Miró JM, Paredes R. Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease. AIDS. 2015 Jul 31; 29(12):1493-504. PMID: 26244389.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    33. Imaz A, Camoez M, Di Yacovo S, Gasch O, Dominguez MA, Vila A, Maso-Serra M, Pujol M, Podzamczer D. Prevalence of methicillin-resistant Staphylococcus aureus colonization in HIV-infected patients in Barcelona, Spain: a cross-sectional study. BMC Infect Dis. 2015 Jun 26; 15:243. PMID: 26113228.
      Citations: 5     Fields:    Translation:HumansCells
    34. Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabié A, Weiss L, Gatell JM. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015 Jul; 15(7):785-92. PMID: 26062880.
      Citations: 34     Fields:    Translation:HumansCells
    35. Miro JM, Manzardo C, Ferrer E, Loncà M, Guardo AC, Podzamczer D, Domingo P, Curran A, Clotet B, Cruceta A, Lozano F, Pérez I, Plana M, Gatell JM. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial). J Acquir Immune Defic Syndr. 2015 Jun 01; 69(2):206-15. PMID: 25831464.
      Citations: 4     Translation:HumansCells
    36. Berenguer J, Polo R, Aldeguer JL, Lozano F, Aguirrebengoa K, Arribas JR, Blanco JR, Boix V, Casado JL, Clotet B, Crespo M, Domingo P, Estrada V, García F, Gatell JM, González-García J, Gutiérrez F, Iribarren JA, Knobel H, Llibre JM, Locutura J, López JC, Miró JM, Moreno S, Podzamczer D, Portilla J, Pulido F, Ribera E, Riera M, Rubio R, Santos J, Sanz-Moreno J, Sanz J, Téllez MJ, Tuset M, Rivero A. Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). Enferm Infecc Microbiol Clin. 2015 Oct; 33(8):544-56. PMID: 26021186.
      Citations: 3     Fields:    Translation:HumansCells
    37. Van den Eynde E, Curto J, Ferrer E, Imaz A, Saumoy M, Di Yacovo S, Vila A, Podzamczer D. Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients. AIDS. 2015 May 15; 29(8):977-9. PMID: 25784438.
      Citations:    Fields:    Translation:Humans
    38. Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015 Jun 27; 385(9987):2606-15. PMID: 25890673.
      Citations: 174     Fields:    Translation:HumansCTClinical Trials
    39. Santos JR, Saumoy M, Curran A, Bravo I, Llibre JM, Navarro J, Estany C, Podzamczer D, Ribera E, Negredo E, Clotet B, Paredes R. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015 Aug 01; 61(3):403-8. PMID: 25870325.
      Citations: 27     Fields:    Translation:Humans
    40. Ribera E, Podzamczer D. [Mechanisms of action, pharmacology and interactions of dolutegravir]. Enferm Infecc Microbiol Clin. 2015 Mar; 33 Suppl 1:2-8. PMID: 25858605.
      Citations:    Fields:    Translation:HumansCells
    41. Di Yacovo MS, Moltó J, Ferrer E, Curran A, Else L, Gisslén M, Clotet B, Tiraboschi JM, Niubò J, Vila A, Zetterberg H, Back D, Podzamczer D. Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. J Antimicrob Chemother. 2015 May; 70(5):1513-6. PMID: 25608583.
      Citations: 3     Fields:    Translation:HumansCells
    42. Viciana-Fernández P, Falcó V, Castaño M, de los Santos-Gil I, Olalla-Sierra J, Hernando A, Deig E, Clotet B, Knobel H, Podzamczer D, Pedrol PD. [Barriers to ART initiation in HIV infected subjects and with treatment indication in Spain. Why don't they start their treatment? Bridgap Study]. Enferm Infecc Microbiol Clin. 2015 Jun-Jul; 33(6):397-403. PMID: 25577557.
      Citations:    Fields:    Translation:Humans
    43. Saumoy M, Ordóñez-Llanos J, Martínez E, Ferrer E, Domingo P, Ribera E, Negredo E, Curto J, Sánchez-Quesada JL, Di Yacovo S, González-Cordón A, Podzamczer D. Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study. J Antimicrob Chemother. 2015 Apr; 70(4):1130-8. PMID: 25538166.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    44. Moltó J, Valle M, Ferrer E, Domingo P, Curran A, Santos JR, Mateo MG, Di Yacovo MS, Miranda C, Podzamczer D, Clotet B. Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. J Antimicrob Chemother. 2015 Apr; 70(4):1139-45. PMID: 25525195.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    45. Martinez E, Gonzalez-Cordon A, Ferrer E, Domingo P, Negredo E, Gutierrez F, Portilla J, Curran A, Podzamczer D, Ribera E, Murillas J, Bernardino JI, Santos I, Carton JA, Peraire J, Pich J, Deulofeu R, Perez I, Gatell JM. Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial. Clin Infect Dis. 2015 Mar 01; 60(5):811-20. PMID: 25389256.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    46. Santos JR, Saumoy M, Curran A, Bravo I, Navarro J, Estany C, Podzamczer D, Ribera E, Negredo E, Clotet B, Paredes R. Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC. J Int AIDS Soc. 2014; 17(4 Suppl 3):19550. PMID: 25394057.
      Citations: 1     Fields:    
    47. Ferrer E, Navarro A, Curto J, Medina P, Rozas N, Barrera G, Saumoy M, Tiraboschi JM, Gomez C, Podzamczer D. Long-term fat redistribution in ARV-naïve HIV+ patients initiating a non-thymidine containing regimen in clinical practice. J Int AIDS Soc. 2014; 17(4 Suppl 3):19553. PMID: 25394060.
      Citations:    Fields:    
    48. Tiraboschi J, Imaz A, Ferrer E, Saumoy M, Rozas N, Maso M, Vila A, Niubo J, Podzamczer D. CSF LPV concentrations and viral load in viral suppressed patients on LPV/r monotherapy given once daily. J Int AIDS Soc. 2014; 17(4 Suppl 3):19587. PMID: 25394093.
      Citations: 1     Fields:    
    49. Podzamczer D, Rojas JF, Neves I, Ferrer E, Llibre JM, Leal M, Gorgolas M, Jose CM, Gatell JM, Abreu RC, Curto J, Domingo P, Pilar BM, Rozas N. Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients. J Int AIDS Soc. 2014; 17(4 Suppl 3):19773. PMID: 25397517.
      Citations:    Fields:    
    50. Podzamczer D, Rozas N, Domingo P, Ocampo A, Van den Eynde E, Deig E, Vergara A, Knobel H, Pasquau J, Antela A, Crespo M, Clotet B, Muñoz J, Fernandez P, Geijo P, de Castro ER, Diz J, Casado A, Torres C. ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study. J Int AIDS Soc. 2014; 17(4 Suppl 3):19814. PMID: 25397558.
      Citations: 2     Fields:    
    51. Di Yacovo S, Molto J, Ferrer E, Curran A, Else LJ, Clotet B, Tiraboschi J, Niubo J, Vila A, Podzamczer D. DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI. J Int AIDS Soc. 2014; 17(4 Suppl 3):19821. PMID: 25397565.
      Citations:    Fields:    
    52. Imaz A, Cayuela N, Niubó J, Tiraboschi JM, Izquierdo C, Cabellos C, Podzamczer D. Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression. AIDS Res Hum Retroviruses. 2014 Oct; 30(10):984-7. PMID: 25096495.
      Citations: 11     Fields:    Translation:Humans
    53. Blasco AJ, Llibre JM, Berenguer J, González-García J, Knobel H, Lozano F, Podzamczer D, Pulido F, Rivero A, Tuset M, Lázaro P, Gatell JM. Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enferm Infecc Microbiol Clin. 2015 Mar; 33(3):156-65. PMID: 25175171.
      Citations: 2     Fields:    Translation:Humans
    54. Van den Eynde E, Podzamczer D. Switch strategies in antiretroviral therapy regimens. Expert Rev Anti Infect Ther. 2014 Sep; 12(9):1055-74. PMID: 25075752.
      Citations: 6     Fields:    Translation:HumansCells
    55. Berenguer J, Polo R, Lozano F, López Aldeguer J, Antela A, Arribas JR, Asensi V, Blanco JR, Clotet B, Domingo P, Galindo MJ, Gatell JM, González-García J, Iribarren JA, Locutura J, López JC, Mallolas J, Martínez E, Miralles C, Miró JM, Moreno S, Palacios R, Pérez Elías MJ, Pineda JA, Podzamczer D, Portilla J, Pulido F, Ribera E, Riera M, Rubio R, Santos J, Sanz J, Tuset M, Vidal F, Rivero A. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). Enferm Infecc Microbiol Clin. 2014 Aug-Sep; 32(7):447-58. PMID: 24986715.
      Citations: 1     Fields:    Translation:Humans
    56. Blanco JL, Gonzalez-Cordón A, Llibre JM, Calvo M, Gutierrez F, Podzamczer D, Laguno M, Fumero E, Murillas J, Mallolas J, Martinez-Rebollar M, Lonca M, Perez I, Gatell JM, Martinez E. Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir. Antivir Ther. 2015; 20(5):487-92. PMID: 24964358.
      Citations:    Fields:    Translation:HumansCells
    57. Van den Eynde E, Ferrer E, Podzamczer D. Acute renal failure and liver toxicity in an HIV/hepatitis C coinfected patient receiving telaprevir and boosted atazanavir. AIDS. 2014 Jun 19; 28(10):1538-9. PMID: 24896804.
      Citations: 3     Fields:    Translation:Humans
    58. Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernán MA. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology. 2014 Jul 08; 83(2):134-41. PMID: 24907236.
      Citations: 54     Fields:    Translation:HumansCells
    59. Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, Garcia F, Ellefsen K, Podzamczer D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy WD, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, Sommerfelt MA, Wendel-Hansen V, Sørensen B. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2014 Apr; 14(4):291-300. PMID: 24525316.
      Citations: 35     Fields:    Translation:HumansCellsCTClinical Trials
    60. Negredo E, Domingo P, Ferrer E, Estrada V, Curran A, Navarro A, Isernia V, Rosales J, Pérez-Álvarez N, Puig J, Bonjoch A, Echeverría P, Podzamczer D, Clotet B. Peak bone mass in young HIV-infected patients compared with healthy controls. J Acquir Immune Defic Syndr. 2014 Feb 01; 65(2):207-12. PMID: 24091689.
      Citations: 13     Translation:Humans
    61. Imaz A, Llibre JM, Navarro J, Curto J, Clotet B, Crespo M, Ferrer E, Saumoy M, Tiraboschi JM, Murillo O, Podzamczer D. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml. Antivir Ther. 2014; 19(6):569-77. PMID: 24458091.
      Citations: 4     Fields:    Translation:HumansCells
    62. Curran A, Monteiro P, Domingo P, Villar J, Imaz A, Martínez E, Fernández I, Knobel H, Podzamczer D, Iribarren JA, Peñaranda M, Crespo M. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group. J Antimicrob Chemother. 2014 May; 69(5):1390-6. PMID: 24415645.
      Citations: 6     Fields:    Translation:HumansCells
    63. Podzamczer D. Lipid metabolism and cardiovascular risk in HIV infection: new perspectives and the role of nevirapine. AIDS Rev. 2013 Oct-Dec; 15(4):195-203. PMID: 24192600.
      Citations: 4     Fields:    Translation:Humans
    64. Blasco AJ, Llibre JM, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, López JC, Lozano F, Miró JM, Podzamczer D, Santamaría JM, Tuset M, Zamora L, Lázaro P, Gatell JM. [Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013]. Enferm Infecc Microbiol Clin. 2013 Nov; 31(9):568-78. PMID: 23969276.
      Citations: 4     Fields:    Translation:Humans
    65. Podzamczer D. [Conclusions. Position of rilpivirine in the management of infection by the human immunodeficiency virus]. Enferm Infecc Microbiol Clin. 2013 Jun; 31 Suppl 2:44. PMID: 24252533.
      Citations:    Fields:    Translation:HumansCells
    66. Podzamczer D. [Introduction. Rilpivirine]. Enferm Infecc Microbiol Clin. 2013 Jun; 31 Suppl 2:1. PMID: 24252526.
      Citations:    Fields:    Translation:Humans
    67. Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, Leal M, Than S, Valluri SR, Craig C, McFadyen L, Vourvahis M, Heera J, Valdez H, Rinehart AR, Portsmouth S. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):164-70. PMID: 23187936.
      Citations: 14     Translation:HumansCells
    68. Podzamczer D, Martínez E, Domingo P, Ferrer E, Viciana P, Curto J, Pérez-Elías MJ, Ocampo A, Santos I, Knobel H, Estrada V, Negredo E, Segura F, Portilla J, Ribera E, Galindo J, Antela A, Carmena J, Castaño M. Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study. Curr HIV Res. 2012 Dec; 10(8):673-8. PMID: 23061598.
      Citations: 1     Fields:    Translation:HumansCells
    69. Martínez E, D'Albuquerque PM, Llibre JM, Gutierrez F, Podzamczer D, Antela A, Berenguer J, Domingo P, Moreno X, Perez I, Pich J, Gatell JM. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS. 2012 Nov 28; 26(18):2315-26. PMID: 23018438.
      Citations: 44     Fields:    Translation:Humans
    70. Llibre JM, Podzamczer D. Effect of efavirenz versus nevirapine in antiretroviral-naive individuals in the HIV-CAUSAL Collaboration Cohort. AIDS. 2012 Oct 23; 26(16):2117-8. PMID: 23052355.
      Citations:    Fields:    Translation:Humans
    71. Imaz A, Cobos-Trigueros N, Falcó V, Dominguez MA, Manzardo C, Pujol M, Curto J, Bartolomé R, Soriano A, Podzamczer D. Community-associated methicillin-resistant Staphylococcus aureus infections in HIV-infected patients in Spain. J Infect. 2013 Feb; 66(2):199-201. PMID: 23072792.
      Citations: 3     Fields:    Translation:HumansCells
    72. Imaz A, Podzamczer D. The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy. AIDS Rev. 2012 Oct-Dec; 14(4):268-78. PMID: 23258301.
      Citations: 5     Fields:    Translation:HumansCells
    73. Saumoy M, Sánchez-Quesada JL, Martínez E, Llibre JM, Ribera E, Knobel H, Gatell JM, Clotet B, Curran A, Curto J, Masó M, Ordoñez-Llanos J, Podzamczer D. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. Atherosclerosis. 2012 Nov; 225(1):200-7. PMID: 23017355.
      Citations: 13     Fields:    Translation:Humans
    74. Haas DW, Mootsikapun P, Ruxrungtham K, Podzamczer D. Clinical perspectives on human genetic screening to prevent nevirapine toxicity. Per Med. 2012 Sep 01; 9(7):773-782. PMID: 23439719.
      Citations:    Fields:    
    75. Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function. Antivir Ther. 2013; 18(1):125-30. PMID: 22805174.
      Citations: 7     Fields:    Translation:HumansCells
    76. Burgos J, Crespo M, Falcó V, Curran A, Navarro J, Imaz A, Domingo P, Podzamczer D, Mateo MG, Villar S, Van den Eynde E, Ribera E, Pahissa A. Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients. J Antimicrob Chemother. 2012 Oct; 67(10):2479-86. PMID: 22729925.
      Citations: 5     Fields:    Translation:HumansCells
    77. Blasco AJ, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, López JC, Llibre JM, Lozano F, Miró JM, Podzamczer D, Santamaría JM, Tuset M, Zamora L, Lázaro P, Gatell JM. [Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]. Enferm Infecc Microbiol Clin. 2012 Jun; 30(6):283-93. PMID: 22525829.
      Citations: 1     Fields:    Translation:Humans
    78. Burgos J, Crespo M, Falcó V, Curran A, Imaz A, Domingo P, Podzamczer D, Mateo MG, Van den Eynde E, Villar S, Ribera E. Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen. J Antimicrob Chemother. 2012 Jun; 67(6):1453-8. PMID: 22378681.
      Citations: 5     Fields:    Translation:HumansCells
    79. Curran A, Martinez E, Podzamczer D, Lonca M, Barragan P, Crespo M, Falco V, Vidal-Sicart S, Imaz A, Martinez M, Gatell JM, Ribera E. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial. Antivir Ther. 2012; 17(4):711-8. PMID: 22374987.
      Citations: 4     Fields:    Translation:HumansCells
    80. Curran A, Martinez E, Saumoy M, del Rio L, Crespo M, Larrousse M, Podzamczer D, Burgos J, Lonca M, Domingo P, Gatell JM, Ribera E. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS. 2012 Feb 20; 26(4):475-81. PMID: 22112606.
      Citations: 24     Fields:    Translation:Humans
    81. Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Niubó J, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D. Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. Antivir Ther. 2012; 17(3):577-83. PMID: 22301439.
      Citations: 1     Fields:    Translation:HumansCells
    82. Murillo O, Mimbrera D, Petit A, Gil H, Anda P, Carrera M, Podzamczer D. Fatal bacillary angiomatosis mimicking an infiltrative vascular tumour in the immune restoration phase of an HIV-infected patient. Antivir Ther. 2012; 17(2):405-7. PMID: 22293094.
      Citations: 1     Fields:    Translation:HumansCells
    83. Blasco AJ, Arribas JR, Clotet B, Domingo P, González-García J, López-Bernaldo JC, Llibre JM, Lozano F, Podzamczer D, Santamaría JM, Tuset M, Zamora L, Lázaro P, Gatell JM. [Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]. Enferm Infecc Microbiol Clin. 2011 Dec; 29(10):721-30. PMID: 22014894.
      Citations:    Fields:    Translation:Humans
    84. Imaz A, Llibre JM, Ribera E, Clotet B, Podzamczer D. The role of inactive nucleoside/nucleotide reverse transcriptase inhibitors in salvage therapy for drug-resistant HIV-1 infection in the era of new classes and new generation antiretrovirals. J Acquir Immune Defic Syndr. 2011 Oct 01; 58(2):e46-8. PMID: 21921728.
      Citations:    Translation:HumansCells
    85. Yuan J, Guo S, Hall D, Cammett AM, Jayadev S, Distel M, Storfer S, Huang Z, Mootsikapun P, Ruxrungtham K, Podzamczer D, Haas DW. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS. 2011 Jun 19; 25(10):1271-80. PMID: 21505298.
      Citations: 55     Fields:    Translation:HumansCells
    86. Podzamczer D, Andrade-Villanueva J, Clotet B, Taylor S, Rockstroh JK, Reiss P, Domingo P, Gellermann HJ, de Rossi L, Cairns V, Soriano V. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). HIV Med. 2011 Jul; 12(6):374-82. PMID: 21518220.
      Citations: 8     Fields:    Translation:HumansCells
    87. Lejeune M, Miró JM, De Lazzari E, García F, Claramonte X, Martínez E, Ribera E, Arrizabalaga J, Arribas JR, Domingo P, Ferrer E, Plana M, Valls ME, Podzamczer D, Pumarola T, Jacquet A, Mallolas J, Gatell JM, Gallart T. Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis. Clin Infect Dis. 2011 Mar 01; 52(5):662-70. PMID: 21292671.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    88. Nelson M, Stellbrink HJ, Podzamczer D, Banhegyi D, Gazzard B, Hill A, van Delft Y, Vingerhoets J, Stark T, Marks S. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS. 2011 Jan 28; 25(3):335-40. PMID: 21150563.
      Citations: 9     Fields:    Translation:HumansCells
    89. Santos JR, Llibre JM, Domingo P, Imaz A, Ferrer E, Podzamczer D, Bravo I, Ribera E, Videla S, Clotet B. Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients. AIDS Res Hum Retroviruses. 2011 Jul; 27(7):713-7. PMID: 21114458.
      Citations: 3     Fields:    Translation:HumansCells
    90. Ferrer E, del Rio L, Martínez E, Curto J, Domingo P, Ribera E, Negredo E, Rosales J, Saumoy M, Ordóñez J, Gatell JM, Podzamczer D. Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults. AIDS Res Hum Retroviruses. 2011 Oct; 27(10):1061-5. PMID: 21166602.
      Citations: 3     Fields:    Translation:HumansCells
    91. Santin M, Casas S, Saumoy M, Andreu A, Moure R, Alcaide F, Ferrer E, Podzamczer D. Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-? release assay, and the development of active tuberculosis in HIV-seropositive persons. Diagn Microbiol Infect Dis. 2011 Jan; 69(1):59-65. PMID: 21146715.
      Citations: 11     Fields:    Translation:HumansCells
    92. Saumoy M, Ordoñez-Llanos J, Martínez E, Barragán P, Ribera E, Bonet R, Knobel H, Negredo E, Loncá M, Curran A, Gatell JM, Podzamczer D. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir. Antivir Ther. 2011; 16(4):459-68. PMID: 21685533.
      Citations: 5     Fields:    Translation:HumansCells
    93. Gathe J, Andrade-Villanueva J, Santiago S, Horban A, Nelson M, Cahn P, Bogner J, Spencer D, Podzamczer D, Yong CL, Nguyen T, Zhang W, Drulak M, Quinson AM. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. Antivir Ther. 2011; 16(5):759-69. PMID: 21817198.
      Citations: 13     Fields:    Translation:HumansCells
    94. Soriano V, Arastéh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, Antunes F, Di Perri G, Podzamczer D, Taylor S, Domingo P, Gellermann H, de Rossi L. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther. 2011; 16(3):339-48. PMID: 21555816.
      Citations: 21     Fields:    Translation:HumansCells
    95. Tiraboschi JM, Niubo J, Curto J, Podzamczer D. Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients. J Acquir Immune Defic Syndr. 2010 Dec 15; 55(5):606-9. PMID: 20706127.
      Citations: 16     Translation:HumansCells
    96. Tiraboschi JM, Niubo J, Curto J, Podzamczer D. Maraviroc concentrations in seminal plasma in HIV-infected patients. J Acquir Immune Defic Syndr. 2010 Dec 15; 55(5):e35-6. PMID: 21931281.
      Citations: 4     Translation:HumansCells
    97. Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, Norden AG, Cavassini M, Rieger A, Khuong-Josses MA, Branco T, Pearce HC, Givens N, Vavro C, Lim ML. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010 Sep; 55(1):49-57. PMID: 20431394.
      Citations: 78     Translation:HumansCells
    98. Barragán P, López-Velez R, Olmo M, Podzamczer D. Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. Am J Trop Med Hyg. 2010 Jul; 83(1):10-2. PMID: 20595469.
      Citations: 3     Fields:    Translation:HumansCells
    99. Imaz A, Pujol M, Barragán P, Domínguez MA, Tiraboschi JM, Podzamczer D. Community associated methicillin-resistant Staphylococcus aureus in HIV-infected patients. AIDS Rev. 2010 Jul-Sep; 12(3):153-63. PMID: 20842204.
      Citations: 9     Fields:    Translation:HumansCells
    100. Miró JM, Manzardo C, Pich J, Domingo P, Ferrer E, Arribas JR, Ribera E, Arrizabalaga J, Loncá M, Cruceta A, de Lazzari E, Fuster M, Podzamczer D, Plana M, Gatell JM. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. AIDS Res Hum Retroviruses. 2010 Jul; 26(7):747-57. PMID: 20624069.
      Citations: 7     Fields:    Translation:HumansCells
    101. Van den Eynde E, Tiraboschi JM, Tural C, Solà R, Mira JA, Podzamczer D, Jou A, Cañete N, Pineda JA, Pahissa A, Crespo M. Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients. AIDS. 2010 Apr 24; 24(7):975-82. PMID: 20299963.
      Citations: 3     Fields:    Translation:HumansCells
    102. Martínez E, Larrousse M, Podzamczer D, Pérez I, Gutiérrez F, Loncá M, Barragán P, Deulofeu R, Casamitjana R, Mallolas J, Pich J, Gatell JM. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS. 2010 Jan 28; 24(3):F1-9. PMID: 20009917.
      Citations: 29     Fields:    Translation:HumansCells
    103. Mothe B, Perez I, Domingo P, Podzamczer D, Ribera E, Curran A, Viladés C, Vidal F, Dalmau D, Pedrol E, Negredo E, Moltó J, Paredes R, Perez-Alvarez N, Gatell JM, Clotet B. HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain. Curr HIV Res. 2009 Nov; 7(6):597-600. PMID: 19929794.
      Citations: 10     Fields:    Translation:HumansCells
    104. Santos JR, Llibre JM, Ferrer E, Domingo P, Imaz A, Moltó J, Martin-Iguacel R, Caum C, Podzamczer D, Clotet B. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression. HIV Clin Trials. 2009 Nov-Dec; 10(6):432-8. PMID: 20133273.
      Citations: 4     Fields:    Translation:HumansCells
    105. Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ, Monforte AD, Sabin C, Podzamczer D, Fätkenheuer G, Staszewski S, Gill J, Sterne JA. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. J Acquir Immune Defic Syndr. 2009 Nov 01; 52(3):357-63. PMID: 19668084.
      Citations: 17     Fields:    Translation:Humans
    106. Martínez E, Arranz JA, Podzamczer D, Loncá M, Sanz J, Barragán P, Ribera E, Knobel H, Roca V, Gutiérrez F, Blanco JL, Mallolas J, Llibre JM, Clotet B, Dalmau D, Segura F, Arribas JR, Cosín J, Barrufet P, Casas E, Ferrer E, Curran A, González A, Pich J, Cruceta A, Arnaiz JA, Miró JM, Gatell JM. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr. 2009 Jul 01; 51(3):290-7. PMID: 19398921.
      Citations: 26     Translation:HumansCells
    107. Podzamczer D, Ferrer E, Martínez E, Del Rio L, Rosales J, Curto J, Ribera E, Barrufet P, Llibre JM, Aranda M. How much fat loss is needed for lipoatrophy to become clinically evident? AIDS Res Hum Retroviruses. 2009 Jun; 25(6):563-7. PMID: 19500014.
      Citations: 10     Fields:    Translation:HumansAnimals
    108. Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, Lazzari Ed, Gatell JM. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr. 2009 May 01; 51(1):29-36. PMID: 19390327.
      Citations: 22     Translation:HumansCells
    109. Gathe J, da Silva BA, Cohen DE, Loutfy MR, Podzamczer D, Rubio R, Gibbs S, Marsh T, Naylor C, Fredrick L, Bernstein B. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr. 2009 Apr 15; 50(5):474-81. PMID: 19225400.
      Citations: 22     Translation:HumansCTClinical Trials
    110. Virgili N, Fisac C, Martínez E, Ribera E, Gatell JM, Podzamczer D. Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir. J Acquir Immune Defic Syndr. 2009 Apr 15; 50(5):552-3. PMID: 19300101.
      Citations: 1     Translation:Humans
    111. Podzamczer D, Olmo M, Sanz J, Boix V, Negredo E, Knobel H, Domingo P, Pineda JA, Vilades C, Quero JH, Force L, Lahoz JG, Muñoz P, Llibre JM, Mariño A, Ortega E, Dalmau D, Gatell JM, Antón E, Sola J, Galindo MJ, Pedrol E, Sanz J, Lima JT, Flores J. Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients. J Acquir Immune Defic Syndr. 2009 Apr 01; 50(4):390-6. PMID: 19214120.
      Citations: 5     Translation:HumansCells
    112. Pulido F, Pérez-Valero I, Delgado R, Arranz A, Pasquau J, Portilla J, Rubio R, González-García J, Miralles P, Pérez-Elías MJ, Ocampo A, Hernando A, Estrada V, Clotet B, Podzamczer D, Arribas JR. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther. 2009; 14(2):195-201. PMID: 19430094.
      Citations: 9     Fields:    Translation:HumansCells
    113. Barragan P, Podzamczer D. Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment. Expert Opin Pharmacother. 2008 Sep; 9(13):2363-75. PMID: 18710360.
      Citations: 6     Fields:    Translation:Humans
    114. Falcó V, Olmo M, del Saz SV, Guelar A, Santos JR, Gutiérrez M, Colomer D, Deig E, Mateo G, Montero M, Pedrol E, Podzamczer D, Domingo P, Llibre JM. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr. 2008 Sep 01; 49(1):26-31. PMID: 18667930.
      Citations: 36     Translation:HumansCells
    115. Ferrer E, Gatell JM, Sanchez P, Domingo P, Puig T, Niubo J, Cortes C, Veloso S, Pedrol E, Leon A, Gutierrez M, Podzamczer D. Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study. AIDS Res Hum Retroviruses. 2008 Jul; 24(7):931-4. PMID: 18671476.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    116. Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain). J Acquir Immune Defic Syndr. 2008 Feb 01; 47(2):212-20. PMID: 18297762.
      Citations: 22     Translation:Humans
    117. Ferrer E, Niubo J, Crespo M, Gatell JM, Sanz J, Veloso S, Llibre JM, Barrufet P, Sanchez P, Podzamczer D. Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz. J Acquir Immune Defic Syndr. 2007 Oct 01; 46(2):253-5. PMID: 17895768.
      Citations:    Translation:HumansCells
    118. Podzamczer D, King MS, Klein CE, Flexner C, Katlama C, Havlir DV, Letendre SL, Eron JJ, Brun SC, Bernstein B. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response. HIV Clin Trials. 2007 Jul-Aug; 8(4):193-204. PMID: 17720659.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    119. Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, Lonca M, Sanz J, Niubo J, Veloso S, Llibre JM, Barrufet P, Ribas MA, Merino E, Ribera E, Martínez-Lacasa J, Alonso C, Aranda M, Pulido F, Berenguer J, Delegido A, Pedreira JD, Lérida A, Rubio R, del Río L. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr. 2007 Feb 01; 44(2):139-47. PMID: 17106274.
      Citations: 32     Translation:Humans
    120. Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Leyes M, Pedrol E, Force L, de Lazzari E, Gatell JM. Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients. AIDS. 2007 Jan 30; 21(3):367-9. PMID: 17255745.
      Citations: 3     Fields:    Translation:HumansCells
    121. Martínez E, López Bernaldo de Quirós JC, Miralles C, Podzamczer D. Considerations on the increase in blood pressure among antiretroviral-naive patients starting HAART. AIDS. 2007 Jan 30; 21(3):384-6. PMID: 17255753.
      Citations:    Fields:    Translation:Humans
    122. Caro-Murillo AM, Castilla J, Pérez-Hoyos S, Miró JM, Podzamczer D, Rubio R, Riera M, Viciana P, López Aldeguer J, Iribarren JA, de los Santos-Gil I, Gómez-Sirvent JL, Berenguer J, Gutiérrez F, Saumoy M, Segura F, Soriano V, Peña A, Pulido F, Oteo JA, Leal M, Casabona J, del Amo J, Moreno S. [Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results]. Enferm Infecc Microbiol Clin. 2007 Jan; 25(1):23-31. PMID: 17261243.
      Citations: 27     Fields:    Translation:Humans
    123. Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev. 2006 Oct-Dec; 8(4):191-203. PMID: 17219734.
      Citations: 8     Fields:    Translation:Humans
    124. Johnson MA, Gathe JC, Podzamczer D, Molina JM, Naylor CT, Chiu YL, King MS, Podsadecki TJ, Hanna GJ, Brun SC. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr. 2006 Oct 01; 43(2):153-60. PMID: 16951643.
      Citations: 35     Translation:HumansCells
    125. Miro JM, Lopez JC, Podzamczer D, Peña JM, Alberdi JC, Martínez E, Domingo P, Cosin J, Claramonte X, Arribas JR, Santín M, Ribera E. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis. 2006 Jul 01; 43(1):79-89. PMID: 16758422.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    126. Olmo M, Podzamczer D. A review of nelfinavir for the treatment of HIV infection. Expert Opin Drug Metab Toxicol. 2006 Apr; 2(2):285-300. PMID: 16866614.
      Citations: 4     Fields:    Translation:HumansCells
    127. Berenguer J, Pérez-Elías MJ, Bellón JM, Knobel H, Rivas-González P, Gatell JM, Miguélez M, Hernández-Quero J, Flores J, Soriano V, Santos I, Podzamczer D, Sala M, Camba M, Resino S. Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort. J Acquir Immune Defic Syndr. 2006 Feb 01; 41(2):154-9. PMID: 16394846.
      Citations: 4     Translation:HumansCells
    128. Condes E, Aguirrebengoa K, Dalmau D, Estrada JM, Force L, Górgolas M, Badia X, Podzamczer D. [Validation of a questionnaire to estimate satisfaction with antiretroviral treatment: CESTA questionnaire]. Enferm Infecc Microbiol Clin. 2005 Dec; 23(10):586-92. PMID: 16324547.
      Citations: 4     Fields:    Translation:Humans
    129. Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamczer D, Liñares J, Gudiol F. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med. 2005 Jul 11; 165(13):1533-40. PMID: 16009870.
      Citations: 37     Fields:    Translation:HumansCells
    130. Fisac C, Fumero E, Crespo M, Roson B, Ferrer E, Virgili N, Ribera E, Gatell JM, Podzamczer D. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS. 2005 Jun 10; 19(9):917-25. PMID: 15905672.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    131. Jaén A, Casabona J, Esteve A, Miró JM, Tural C, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Masabeu A, García I, Dorca E, Altès J, Navarro G, Podzamczer D, Villalonga C, Clotet B, Gatell JM. [Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]. Med Clin (Barc). 2005 Apr 16; 124(14):525-31. PMID: 15847748.
      Citations: 10     Fields:    Translation:Humans
    132. Podzamczer D, Ferrer E, Gatell JM, Niubo J, Dalmau D, Leon A, Knobel H, Polo C, Iniguez D, Ruiz I. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antivir Ther. 2005; 10(1):171-7. PMID: 15751775.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    133. Badía X, Podzamczer D, Moral I, Roset M, Arnaiz JA, Loncà M, Casiró A, Rosón B, Gatell JM. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy. Antivir Ther. 2004 Dec; 9(6):979-85. PMID: 15651756.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    134. Martin-Carbonero L, Barrios A, Saballs P, Sirera G, Santos J, Palacios R, Valencia ME, Alegre M, Podzamczer D, González-Lahoz J. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS. 2004 Aug 20; 18(12):1737-40. PMID: 15280789.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    135. Ferrer E, Santamariña E, Domingo P, Fumero E, Ribera E, Knobel H, Lopez JC, Barrios A, Podzamczer D. Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less. AIDS. 2004 Aug 20; 18(12):1727-9. PMID: 15280785.
      Citations: 3     Fields:    Translation:Humans
    136. Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine. Antivir Ther. 2004 Apr; 9(2):197-204. PMID: 15134181.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    137. Fisac C, Virgili N, Ferrer E, Barbera MJ, Fumero E, Vilarasau C, Podzamczer D. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study. J Clin Endocrinol Metab. 2003 Nov; 88(11):5186-92. PMID: 14602748.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    138. Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003 Sep 11; 349(11):1036-46. PMID: 12968087.
      Citations: 46     Fields:    Translation:HumansCellsCTClinical Trials
    139. Arnaiz JA, Mallolas J, Podzamczer D, Gerstoft J, Lundgren JD, Cahn P, Fätkenheuer G, D'Arminio-Monforte A, Casiró A, Reiss P, Burger DM, Stek M, Gatell JM. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS. 2003 Apr 11; 17(6):831-40. PMID: 12660530.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    140. Ferrer E, Podzamczer D, Arnedo M, Fumero E, McKenna P, Rinehart A, Pérez JL, Barberá MJ, Pumarola T, Gatell JM, Gudiol F. Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine. J Infect Dis. 2003 Feb 15; 187(4):687-90. PMID: 12599088.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    141. Núnez M, de Mendoza C, Valer L, Casas E, López-Calvo S, Castro A, Rosón B, Podzamczer D, Rubio A, Berenguer J, Soriano V. Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations. Med Sci Monit. 2002 Sep; 8(9):CR620-3. PMID: 12218942.
      Citations: 3     Fields:    Translation:HumansCells
    142. Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther. 2002 Jun; 7(2):81-90. PMID: 12212928.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    143. Podzamczer D, Miralles P, La Calle Md Md, Zarco C, Berenguer J, López Aldeguer J, Valencia E, Rubio R, Ribera JM. [Recommendations of GESIDA/Spanish National Plan of AIDS on diagnosis and treatment of Kaposi's sarcoma and cervical cancer in HIV-infected patients]. Med Clin (Barc). 2002 Jun 01; 118(20):788-95. PMID: 12049697.
      Citations: 1     Fields:    Translation:Humans